Squalamine lactate (MSI-1256F) (Synonyms: MSI-1256F) |
| Katalog-Nr.GC32161 |
Squalaminlactat (MSI-1256F) ist eine Aminosterolverbindung, die im Gewebe des Dornhais entdeckt wurde, mit antimikrobieller AktivitÄt und zur Behandlung von neovaskulÄrer altersbedingter Makuladegeneration verwendet wird.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 320725-47-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Squalamine lactate is an aminosterol compound discovered in the tissues of the dogfish shark, with antimicrobial activity, and used for the treatment of neovascular age-related macular degeneration.
Squalamine lactate has a more generalized effect on the cellular signaling cascade that is common to both VEGF and other growth factors[1]. Squalamine blocks the action of VEGF and integrin expression, thereby inhibiting angiogenesis, when bound to calmodulin[2].
Squalamine is ineffective when administered intravitreally and therefore requires intravenous dosing. However, systemic dosing has yielded promising results in rats as well as humans[2].
[1]. Hussain RM, et al. Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration. Expert Opin Emerg Drugs. 2017 Sep;22(3):235-246. [2]. Emerson MV, et al. Current and emerging therapies for the treatment of age-related macular degeneration. Clin Ophthalmol. 2008 Jun;2(2):377-88.
Average Rating: 5 (Based on Reviews and 29 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *